PDS Biotechnology Corporation (NASDAQ: PDSB) stock fell -4.41% on Friday to $6.29 against a previous-day closing price of $6.58. With 0.59 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.49 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $6.74 whereas the lowest price it dropped to was $6.24. The 52-week range on PDSB shows that it touched its highest point at $13.65 and its lowest point at $3.80 during that stretch. It currently has a 1-year price target of $17.67. Beta for the stock currently stands at 2.13.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PDSB was up-trending over the past week, with a rise of 17.79%, but this was up by 52.30% over a month. Three-month performance surged to 12.12% while six-month performance fell -15.11%. The stock lost -25.83% in the past year, while it has lost -52.35% so far this year. A look at the trailing 12-month EPS for PDSB yields -1.71 with Next year EPS estimates of -1.69. For the next quarter, that number is -0.41. This implies an EPS growth rate of -1.50% for this year and -16.73% for next year.
Float and Shares Shorts:
At present, 30.17 million PDSB shares are outstanding with a float of 29.58 million shares on hand for trading. On Oct 30, 2023, short shares totaled 5.52 million, which was 17.87% higher than short shares on Sep 28, 2023. In addition to Dr. Frank K. Bedu-Addo Ph.D. as the firm’s President, CEO & Director, Mr. Matthew C. Hill CPA serves as its CFO, Principal Financial & Accounting Officer.
Through their ownership of 25.12% of PDSB’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 7.22% of PDSB, in contrast to 13.14% held by mutual funds. Shares owned by individuals account for 11.96%. As the largest shareholder in PDSB with 5.43% of the stake, BlackRock Fund Advisors holds 1,674,871 shares worth 1,674,871. A second-largest stockholder of PDSB, The Vanguard Group, Inc., holds 1,444,858 shares, controlling over 4.68% of the firm’s shares. Geode Capital Management LLC is the third largest shareholder in PDSB, holding 601,360 shares or 1.95% stake. With a 2.74% stake in PDSB, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 845,684 shares are owned by the mutual fund manager. The iShares Russell 2000 ETF, which owns about 2.08% of PDSB stock, is the second-largest Mutual Fund holder. It holds 641,745 shares valued at 2.68 million. Vanguard Extended Market Index Fu holds 1.34% of the stake in PDSB, owning 413,644 shares worth 1.72 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PDSB since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With PDSB analysts setting a high price target of $21.00 and a low target of $14.00, the average target price over the next 12 months is $17.67. Based on these targets, PDSB could surge 233.86% to reach the target high and rise by 122.58% to reach the target low. Reaching the average price target will result in a growth of 180.92% from current levels.
Summary of Insider Activity:
Insiders traded PDSB stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 1 while that of sell transactions has risen to 1 over the past year. The total number of shares bought during that period was 219,535 while 175,184 shares were sold.